Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease

REFERENCES

1. 1.↵
   1. Turnheim K,
   2. Krivanek P,
   3. Oberbauer R

   . Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999;48:501–9.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Bruce SP

   . Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187–94.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Lim DH,
   2. Oh JS,
   3. Ahn SM,
   4. Hong S,
   5. Kim YG,
   6. Lee CK,
   7. et al.

   Febuxostat in hyperuricemic patients with advanced CKD. Am J Kidney Dis 2016;68:819–21.

   OpenUrl
4. 4.↵
   1. National Institutes of Health and LiverTox

   . Drug record: Febuxostat. [Internet. Accessed October 29, 2018.] Available from: https://livertox.nlm.nih.gov/Febuxostat.htm
5. 5.↵
   1. National Institutes of Health and LiverTox

   . Drug record: Allopurinol. [Internet. Accessed October 29, 2018.] Available from: https://livertox.nlm.nih.gov/Allopurinol.htm
6. 6.↵
   1. Becker MA,
   2. Schumacher HR Jr,
   3. Wortmann RL,
   4. MacDonald PA,
   5. Eustace D,
   6. Palo WA,
   7. et al.

   Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450–61.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Bohm M,
   2. Vuppalanchi R,
   3. Chalasani N;
   4. Drug-Induced Liver Injury Network

   . Febuxostat-induced acute liver injury. Hepatology 2016;63:1047–9.

   OpenUrl
8. 8.↵
   Febuxostat: hepatic failure. Prescrire Int 2013;22:297.

   OpenUrl
9. 9.↵
   1. Kuo CF,
   2. Yu KH,
   3. Luo SF,
   4. Chiu CT,
   5. Ko YS,
   6. Hwang JS,
   7. et al.

   Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol 2010;39:466–71.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Li Y,
    2. Xu C,
    3. Yu C,
    4. Xu L,
    5. Miao M

    . Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029–34.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Puig JG,
    2. Martínez MA

    . Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20:187–91.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Tarantino G,
    2. Conca P,
    3. Basile V,
    4. Gentile A,
    5. Capone D,
    6. Polichetti G,
    7. et al.

    A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410–5.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Neogi T,
    2. Jansen TL,
    3. Dalbeth N,
    4. Fransen J,
    5. Schumacher HR,
    6. Berendsen D,
    7. et al.

    2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015;74:1789–98.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Lee SS,
    2. Park SH,
    3. Kim HJ,
    4. Kim SY,
    5. Kim MY,
    6. Kim DY,
    7. et al.

    Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010;52:579–85.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Lewis JH,
    2. Mortensen ME,
    3. Zweig S,
    4. Fusco MJ,
    5. Medoff JR,
    6. Belder R;
    7. Pravastatin in Chronic Liver Disease Study Investigators

    . Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453–63.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Sharma P,
    2. Tyagi P,
    3. Singla V,
    4. Bansal N,
    5. Kumar A,
    6. Arora A

    . Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol 2015;5:8–13.

    OpenUrl
17. 17.↵
    1. Tang W,
    2. Mu J,
    3. Chen QI,
    4. Li X,
    5. Liu H

    . The involvement and mechanism of febuxostat in non-alcoholic fatty liver disease cells. J Biol Regul Homeost Agents 2018;32:545–51.

    OpenUrl
18. 18.↵
    1. Chalasani N,
    2. Bonkovsky HL,
    3. Fontana R,
    4. Lee W,
    5. Stolz A,
    6. Talwalkar J,
    7. et al;
    8. United States Drug Induced Liver Injury Network

    . Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015;148:1340–52.e7.

    OpenUrlPubMed
19. 19.↵
    1. García-Cortés M,
    2. Stephens C,
    3. Lucena MI,
    4. Fernández-Castañer A,
    5. Andrade RJ

    . Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55:683–91.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Chalasani N,
    2. Björnsson E

    . Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246–59.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Iryna K,
    2. Helen M,
    3. Elena S

    . Drug-induced liver disease in patients with diabetes mellitus. Euroasian J Hepatogastroenterol 2015;5:83–6.

    OpenUrl
22. 22.↵
    1. Oltmanns D,
    2. Dennin DE,
    3. Pentz R,
    4. Siegers CP

    . [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus]. [Article in German] Z Gastroenterol 1984;22:598–601.

    OpenUrlPubMed
23. 23.↵
    1. National Institutes of Health and LiverTox

    . Drug record: Colchicine. [Internet. Accessed October 29, 2018.] Available from: https://livertox.nlm.nih.gov/Colchicine.htm.
24. 24.↵
    1. Abbott CE,
    2. Xu R,
    3. Sigal SH

    . Colchicine-induced hepatotoxicity. ACG Case Rep J 2017;4:e120.

    OpenUrl
25. 25.↵
    1. Gautam M,
    2. Islam T,
    3. Shaikh N,
    4. Singh S

    . Colchicine: an unusual cause of acute hepatitis [abstract]. Am J Gastroenterol Suppl 2003;98:S98.

    OpenUrl
26. 26.↵
    1. Slobodnick A,
    2. Shah B,
    3. Krasnokutsky S,
    4. Pillinger MH

    . Update on colchicine, 2017. Rheumatology 2018;57 suppl 1:i4–i11.

    OpenUrl
27. 27.↵
    1. Rambaldi A,
    2. Gluud C

    . Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 2001;21:129–36.

    OpenUrlCrossRefPubMed